Guerbet
ISIN: FR0000032526 | Ticker: GBT | LEI: 969500WV1U1WQ059L135
Country: France
At Guerbet, we build lasting relationships so that we enable people to live better. This is our Purpose. We place human cooperation at the heart of our relationships and actions.
We are a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging.
A pioneer since 95 years in the field of contrast media, we are a team of over 2,600 people globally, continuously innovating with 10% of revenue dedicated to Research & Development across four centers in France, Israel and the United States.
1926
Served areaWorldwide
Headcount2,730
HeadquartersZone Paris Nord II 15 Rue des Vanesses, 93420 Villepinte – France
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 945,707,000.00 | 1,000,833,000.00 | 939,643,000.00 |
| Noncurrent Assets | N/A | 477,147,000.00 | 505,379,000.00 | 429,970,000.00 |
| Property Plant And Equipment | N/A | 261,294,000.00 | 274,046,000.00 | 286,119,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 188,267,000.00 | 188,618,000.00 | N/A |
| Deferred Tax Assets | N/A | 11,046,000.00 | 19,419,000.00 | 16,653,000.00 |
| Other Noncurrent Financial Assets | N/A | 16,540,000.00 | 23,295,000.00 | 29,273,000.00 |
| Current Assets | N/A | 468,559,000.00 | 495,454,000.00 | 509,673,000.00 |
| Inventories | N/A | 204,587,000.00 | 201,952,000.00 | 272,496,000.00 |
| Other Current Financial Assets | N/A | 56,220,000.00 | 59,000,000.00 | 63,955,000.00 |
| Cash and cash equivalents | N/A | 96,713,000.00 | 115,728,000.00 | 41,683,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | N/A | N/A | 0.00 | 10,300,000.00 |
| Equity And Liabilities | N/A | 945,707,000.00 | 1,000,833,000.00 | 939,643,000.00 |
| Equity | 389,192,000.00 | 367,754,000.00 | 405,092,000.00 | 379,570,000.00 |
| Issued Capital | N/A | 12,603,000.00 | 12,641,000.00 | 12,641,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | 32,637,000.00 | -41,116,000.00 |
| Other Reserves | N/A | 397,461,000.00 | 408,234,000.00 | 444,835,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 364,305,000.00 | 405,092,000.00 | 379,570,000.00 |
| Noncurrent Liabilities | N/A | 377,736,000.00 | 358,873,000.00 | 320,453,000.00 |
| Noncurrent Provisions | N/A | 40,289,000.00 | 41,988,000.00 | 32,150,000.00 |
| Deferred Tax Liabilities | N/A | 14,766,000.00 | 15,246,000.00 | 9,872,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 4,305,000.00 | 1,947,000.00 | 0.00 |
| Current Liabilities | N/A | 200,216,000.00 | 236,869,000.00 | 239,620,000.00 |
| Other Shortterm Provisions | N/A | N/A | 9,774,000.00 | 13,912,000.00 |
| Trade And Other Current Payables | N/A | 64,413,000.00 | 81,021,000.00 | 103,711,000.00 |
| Current Tax Liabilities Current | N/A | 8,086,000.00 | 15,011,000.00 | 19,366,000.00 |
| Liabilities Included In Disposal Groups Classified As Held For Sale | N/A | N/A | 0.00 | 0.00 |
| Other Current Liabilities | N/A | 88,438,000.00 | 97,217,000.00 | 69,021,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 712,295,000.00 | 732,071,000.00 | 753,275,000.00 |
| Revenue From Royalties | 0.00 | 0.00 | 8,001,000.00 |
| Interest Income On Cash And Cash Equivalents | 83,000.00 | 59,000.00 | 34,000.00 |
| Other Income | 5,397,000.00 | 4,941,000.00 | 8,879,000.00 |
| Raw Materials And Consumables Used | 166,552,000.00 | 190,934,000.00 | 180,424,000.00 |
| Services Expense | 203,975,000.00 | 195,565,000.00 | 232,585,000.00 |
| Employee Benefits Expense | 236,500,000.00 | 232,789,000.00 | 240,664,000.00 |
| Depreciation And Amortisation Expense | 59,649,000.00 | 55,945,000.00 | 119,625,000.00 |
| Tax Expense Other Than Income Tax Expense | 15,852,000.00 | 13,459,000.00 | 14,992,000.00 |
| Profit Loss From Operating Activities | 41,872,000.00 | 38,685,000.00 | -18,160,000.00 |
| Income Tax Expense Continuing Operations | 4,008,000.00 | -3,664,000.00 | 12,744,000.00 |
| Profit (loss) | 18,240,000.00 | 32,637,000.00 | -41,116,000.00 |
| Profit Loss Attributable To Owners Of Parent | 18,240,000.00 | 32,637,000.00 | -41,116,000.00 |
| Line item in (eur) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | 18,240,000.00 | 32,637,000.00 | -41,116,000.00 |
| Adjustments For Income Tax Expense | 4,008,000.00 | -3,664,000.00 | 12,744,000.00 |
| Adjustments For Decrease Increase In Inventories | 17,383,000.00 | 4,578,000.00 | -68,228,000.00 |
| Adjustments For Depreciation And Amortisation Expense | 57,741,000.00 | 58,320,000.00 | 123,134,000.00 |
| Adjustments For Provisions | 1,379,000.00 | 8,316,000.00 | 382,000.00 |
| Adjustments For Sharebased Payments | -1,307,000.00 | 610,000.00 | -399,000.00 |
| Adjustments For Fair Value Gains Losses | -168,000.00 | 443,000.00 | -1,358,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | 5,367,000.00 | 286,000.00 | 2,273,000.00 |
| Cash Flows From Used In Operating Activities | 120,432,000.00 | 115,973,000.00 | 30,441,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | 1,644,000.00 | 840,000.00 | 1,194,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 39,792,000.00 | 37,500,000.00 | 43,835,000.00 |
| Proceeds From Sales Of Intangible Assets Classified As Investing Activities | 1,038,000.00 | 720,000.00 | 720,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 19,890,000.00 | 11,431,000.00 | 6,688,000.00 |
| Cash Flows From Used In Investing Activities | -57,288,000.00 | -52,243,000.00 | -55,398,000.00 |
| Proceeds From Issuing Shares | 100,000.00 | 592,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | 7,337,000.00 | 6,581,000.00 | 2,398,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | 40,607,000.00 | 34,392,000.00 | 35,659,000.00 |
| Dividends Paid Classified As Financing Activities | 8,825,000.00 | 8,814,000.00 | 10,733,000.00 |
| Interest Paid Classified As Financing Activities | 4,890,000.00 | 5,250,000.00 | 4,552,000.00 |
| Cash Flows From Used In Financing Activities | -46,887,000.00 | -41,283,000.00 | -48,546,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -3,699,000.00 | 68,000.00 | -620,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | 12,560,000.00 | 22,515,000.00 | -74,122,000.00 |
| Cash and cash equivalents | 96,713,000.00 | 115,728,000.00 | 41,683,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 04.05.23 | None | Other | Buy | EUR 4,938.00 |
FR0000032526
LEI969500WV1U1WQ059L135
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.